BACKGROUND: Binding of adenosine to the anti-inflammatory Gs-coupled adenosine 2A receptor (A(2A)R) inhibits the activity of most inflammatory cells. Extensive preclinical evidence exists for the use of A(2A)R agonists in the prevention of acute ischemia-reperfusion injury. Activation of A(2A)Rs on lymphocytes and antigen-presenting cells also attenuates the alloimmune response. Because ischemia-reperfusion injury and alloimmunity are risk factors for the development of bronchiolitis obliterans (BO), the objective of this study was to determine the effect of A(2A)R signaling on tracheal rejection in a mouse model of BO. METHODS: A non-revascularized heterotopic tracheal model across a total alloantigenic mismatch was used to study A(2A)R signaling in a mouse model of BO. Tracheal transplants were performed using Balb/c donors into wild-type or A(2A)R knockout C57BL/6 recipient mice. Another group of Balb/c transplants into C57BL/6 recipients were also treated with a selective A(2A)R agonist. Tracheas were assessed at 3, 7, 12, 21, and 28 days after transplantation by hematoxylin and eosin staining, immunohistochemical staining, and collagen staining. RESULTS: Compared with allograft tracheas in wild-type recipients, allografts in A(2A)R knockout recipients had increased inflammation and more severe BO development. Recipient wild-type mice treated with a selective A(2A)R agonist were significantly protected from lymphocyte infiltration and luminal occlusion, but fibro-obliteration still developed by 28 days after transplantation. CONCLUSIONS: Endogenous adenosine signals through the A(2A)R to attenuate inflammatory and immune factors involved in BO development. Synthetic A(2A)R agonists may provide a novel treatment strategy to prevent BO.
BACKGROUND: Binding of adenosine to the anti-inflammatory Gs-coupled adenosine 2A receptor (A(2A)R) inhibits the activity of most inflammatory cells. Extensive preclinical evidence exists for the use of A(2A)R agonists in the prevention of acute ischemia-reperfusion injury. Activation of A(2A)Rs on lymphocytes and antigen-presenting cells also attenuates the alloimmune response. Because ischemia-reperfusion injury and alloimmunity are risk factors for the development of bronchiolitis obliterans (BO), the objective of this study was to determine the effect of A(2A)R signaling on tracheal rejection in a mouse model of BO. METHODS: A non-revascularized heterotopic tracheal model across a total alloantigenic mismatch was used to study A(2A)R signaling in a mouse model of BO. Tracheal transplants were performed using Balb/c donors into wild-type or A(2A)R knockout C57BL/6 recipient mice. Another group of Balb/c transplants into C57BL/6 recipients were also treated with a selective A(2A)R agonist. Tracheas were assessed at 3, 7, 12, 21, and 28 days after transplantation by hematoxylin and eosin staining, immunohistochemical staining, and collagen staining. RESULTS: Compared with allograft tracheas in wild-type recipients, allografts in A(2A)R knockout recipients had increased inflammation and more severe BO development. Recipient wild-type mice treated with a selective A(2A)R agonist were significantly protected from lymphocyte infiltration and luminal occlusion, but fibro-obliteration still developed by 28 days after transplantation. CONCLUSIONS: Endogenous adenosine signals through the A(2A)R to attenuate inflammatory and immune factors involved in BO development. Synthetic A(2A)R agonists may provide a novel treatment strategy to prevent BO.
Authors: Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky Journal: Proc Natl Acad Sci U S A Date: 2006-08-17 Impact factor: 11.205
Authors: Zequan Yang; Yuan-Ji Day; Marie-Claire Toufektsian; Yaqin Xu; Susan I Ramos; Melissa A Marshall; Brent A French; Joel Linden Journal: Circulation Date: 2006-10-23 Impact factor: 29.690
Authors: Makoto Naganuma; Elizabeth B Wiznerowicz; Courtney M Lappas; Joel Linden; Mark T Worthington; Peter B Ernst Journal: J Immunol Date: 2006-09-01 Impact factor: 5.422
Authors: Shiraz A Daud; Roger D Yusen; Bryan F Meyers; Murali M Chakinala; Michael J Walter; Aviva A Aloush; G Alexander Patterson; Elbert P Trulock; Ramsey R Hachem Journal: Am J Respir Crit Care Med Date: 2006-12-07 Impact factor: 21.405
Authors: Andreas A Erdmann; Zhan-Guo Gao; Unsu Jung; Jason Foley; Todd Borenstein; Kenneth A Jacobson; Daniel H Fowler Journal: Blood Date: 2005-03-03 Impact factor: 22.113
Authors: Yunge Zhao; Damien J LaPar; John Steidle; Abbas Emaminia; Irving L Kron; Gorav Ailawadi; Joel Linden; Christine L Lau Journal: J Heart Lung Transplant Date: 2010-12 Impact factor: 10.247
Authors: Paul D DiMusto; Guanyi Lu; Abhijit Ghosh; Karen J Roelofs; Gang Su; Yunge Zhao; Christine L Lau; Omar Sadiq; Brendan McEvoy; Adriana Laser; Jose A Diaz; Thomas W Wakefield; Peter K Henke; Jonathan L Eliason; Gilbert R Upchurch Journal: Am J Physiol Heart Circ Physiol Date: 2012-02-03 Impact factor: 4.733
Authors: Yunge Zhao; Jacob R Gillen; Akshaya K Meher; Jordan A Burns; Irving L Kron; Christine L Lau Journal: J Thorac Cardiovasc Surg Date: 2015-09-07 Impact factor: 5.209
Authors: Jacob R Gillen; Yunge Zhao; David A Harris; Damien J LaPar; Irving L Kron; Christine L Lau Journal: Ann Thorac Surg Date: 2013-06-24 Impact factor: 4.330
Authors: David A Harris; Yunge Zhao; Damien J LaPar; Abbas Emaminia; John F Steidle; Mark Stoler; Joel Linden; Irving L Kron; Christine L Lau Journal: J Thorac Cardiovasc Surg Date: 2012-05-22 Impact factor: 5.209
Authors: Guanyi Lu; Gang Su; John P Davis; Basil Schaheen; Emily Downs; R Jack Roy; Gorav Ailawadi; Gilbert R Upchurch Journal: J Vasc Surg Date: 2017-03-06 Impact factor: 4.268
Authors: Guanyi Lu; Gang Su; Yunge Zhao; William F Johnston; Nicholas E Sherman; Emilie F Rissman; Christine Lau; Gorav Ailawadi; Gilbert R Upchurch Journal: J Surg Res Date: 2013-12-03 Impact factor: 2.192
Authors: Yunge Zhao; Jacob R Gillen; David A Harris; Irving L Kron; Michael P Murphy; Christine L Lau Journal: J Thorac Cardiovasc Surg Date: 2013-11-04 Impact factor: 5.209